환자 유래 이종이식 모델 시장 분석 및 예측(-2035년) : 유형, 제품, 서비스, 기술, 용도, 최종사용자, 마우스 모델

The global Patient-Derived Xenograft (PDX) Model Market is projected to grow from $0.4 billion in 2025 to $1.1 billion by 2035, at a compound annual growth rate (CAGR) of 12.1%. Rising government and private funding for cancer research is accelerating the adoption of Patient-Derived Xenograft (PDX) models globally. In October 2024, the UK National Institute for Health Research (NIHR) and the Office for Life Sciences (OLS) invested USD 14.01 million in six cancer research projects supporting advanced preclinical models, including PDX. Similarly, China is expanding investments in immuno-oncology, leveraging PDX models for tumor-immune interaction studies and CAR-T development. Growth in biotechnology and pharmaceutical sectors further drives demand. In October 2025, Japan's National Cancer Center launched the J-PDX Library, strengthening translational oncology research and precision medicine-driven drug development initiatives.

Tumor types in preclinical research encompass a wide range of malignancies studied to understand disease progression and therapeutic response. Gastro-intestinal tumors provide insights into colorectal and gastric cancers, while gynecological tumors focus on ovarian and uterine malignancies. Respiratory tumors include lung cancer models, and central nervous system tumors address glioblastoma and related brain cancers. Hematological malignancies cover leukemias and lymphomas, whereas dermatological tumors explore skin cancers such as melanoma. Other solid tumors represent diverse cancers outside these categories. Together, these classifications enable researchers to replicate human disease biology and evaluate novel therapies across multiple cancer indications.

Animal models are essential tools in oncology research, providing controlled systems to study tumor biology and therapeutic interventions. Mice models are widely used due to their genetic manipulability, short reproductive cycles, and availability of immunodeficient strains that support human tumor xenografts. Rat models, larger in size, allow for more complex surgical procedures and pharmacological studies, offering complementary insights. Both models serve as platforms for drug efficacy testing, biomarker discovery, and translational research. Their use bridges the gap between in vitro experiments and clinical trials, ensuring that candidate therapies are evaluated in living systems before advancing to human studies.

Geographical Overview

North America dominated the Patient-Derived Xenograft (PDX) model market with a 48.2% share in 2025, driven by the rising cancer burden and increasing demand for predictive, patient-relevant preclinical models. The region's strong research infrastructure and high healthcare spending further support market expansion. In 2024, the United States is projected to record approximately 2,001,140 new cancer cases and 611,720 deaths, marking a record-high incidence. This growth is attributed to population aging, improved diagnostic capabilities, and wider screening adoption, all of which are intensifying the need for advanced oncology research models like PDX for effective drug development and precision medicine.

Asia-Pacific is the fastest-growing region in the Patient-Derived Xenograft (PDX) model market, with a CAGR of 14.8% during the forecast period. Growth is driven by a high and rising cancer burden alongside expanding oncology research capabilities across the region. According to Pfizer, major Asian countries account for approximately 3.6 million male and 4.0 million female cancer patients, with China alone representing 1.6 million males and 1.5 million females. China has developed extensive PDX libraries covering gastrointestinal, lung, liver, and esophageal cancers, preserving tumor histology and drug response, thereby supporting advanced preclinical research, precision medicine, and accelerated oncology drug development.

Key Trends and Drivers

Rising Adoption of CRISPR-Engineered Humanized PDX Models

Rising adoption of CRISPR-engineered humanized Patient-Derived Xenograft (PDX) models is emerging as a key trend in the global market, driven by the need for more translationally relevant platforms in immuno-oncology and targeted therapy research. These advanced models combine patient tumor tissues with humanized immune systems, enabling more accurate evaluation of therapeutic responses. Industry players are increasingly commercializing gene-edited PDX platforms to strengthen their offerings. For instance, Biocytogen Pharmaceuticals has expanded its BioMice(R) platform with genetically engineered and immune-humanized mouse models developed using precise gene editing, enhancing the ability to replicate human physiological and pathological conditions for oncology research and immunotherapy development.

Rising Outsourcing of PDX Models to CROs Accelerates Market Expansion

Rising outsourcing of Patient-Derived Xenograft (PDX) models to contract research organizations (CROs) is accelerating market expansion, as pharmaceutical and biotechnology companies increasingly rely on external partners for specialized preclinical oncology research. Expanding drug pipelines and limited in-house capacities are driving sponsors toward CROs with advanced PDX expertise. Outsourcing enables access to specialized infrastructure, technical capabilities, and scalable vivarium facilities, while reducing operational costs and accelerating translational timelines. For instance, InnoSer offers comprehensive oncology CRO services with PDX mouse models that allow sponsors to evaluate therapeutic efficacy by accurately replicating tumor heterogeneity and treatment responses in vivo, supporting efficient drug development processes.

Research Scope

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Strategic Recommendations
• 1.5 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Mice Model
• 2.4 Key Market Highlights by Services
• 2.5 Key Market Highlights by Application
• 2.6 Key Market Highlights by End User
• 2.7 Key Market Highlights by Technology

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Technologies Landscape
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTLE Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Gastro-Intestinal Tumors
  • 4.1.2 Gynecological Tumors
  • 4.1.3 Respiratory Tumors
  • 4.1.4 Central Nervous System Tumors
  • 4.1.5 Hematological Malignancies
  • 4.1.6 Dermatological Tumors
  • 4.1.7 Other Solid Tumors
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Mice Models
  • 4.2.2 Rat Models
• 4.3 Market Size & Forecast by Mice Model (2020-2035)
  • 4.3.1 Nude (Athymic)
  • 4.3.2 NOD/SCID
  • 4.3.3 NSG
  • 4.3.4 Humanized Mice
• 4.4 Market Size & Forecast by Services (2020-2035)
  • 4.4.1 Model Creation & Expansion
  • 4.4.2 Model Characterization
  • 4.4.3 Cryopreservation
  • 4.4.4 Other Services
• 4.5 Market Size & Forecast by Application (2020-2035)
  • 4.5.1 Preclinical Research
  • 4.5.2 Biomarker Analysis
  • 4.5.3 Translational Research
  • 4.5.4 Biobanking
• 4.6 Market Size & Forecast by End User (2020-2035)
  • 4.6.1 Pharma & Biotechnology Companies
  • 4.6.2 CROs & CDMOs
  • 4.6.3 Academics & Research Institutes
• 4.7 Market Size & Forecast by Technology (2020-2035)
  • 4.7.1 Heterotopic (Subcutaneous) Implantation
  • 4.7.2 Orthotopic Implantation

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Mice Model
    • 5.2.1.4 Services
    • 5.2.1.5 Application
    • 5.2.1.6 End User
    • 5.2.1.7 Technology
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Mice Model
    • 5.2.2.4 Services
    • 5.2.2.5 Application
    • 5.2.2.6 End User
    • 5.2.2.7 Technology
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Mice Model
    • 5.2.3.4 Services
    • 5.2.3.5 Application
    • 5.2.3.6 End User
    • 5.2.3.7 Technology
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Mice Model
    • 5.3.1.4 Services
    • 5.3.1.5 Application
    • 5.3.1.6 End User
    • 5.3.1.7 Technology
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Mice Model
    • 5.3.2.4 Services
    • 5.3.2.5 Application
    • 5.3.2.6 End User
    • 5.3.2.7 Technology
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Mice Model
    • 5.3.3.4 Services
    • 5.3.3.5 Application
    • 5.3.3.6 End User
    • 5.3.3.7 Technology
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Mice Model
    • 5.4.1.4 Services
    • 5.4.1.5 Application
    • 5.4.1.6 End User
    • 5.4.1.7 Technology
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Mice Model
    • 5.4.2.4 Services
    • 5.4.2.5 Application
    • 5.4.2.6 End User
    • 5.4.2.7 Technology
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Mice Model
    • 5.4.3.4 Services
    • 5.4.3.5 Application
    • 5.4.3.6 End User
    • 5.4.3.7 Technology
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Mice Model
    • 5.4.4.4 Services
    • 5.4.4.5 Application
    • 5.4.4.6 End User
    • 5.4.4.7 Technology
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Mice Model
    • 5.4.5.4 Services
    • 5.4.5.5 Application
    • 5.4.5.6 End User
    • 5.4.5.7 Technology
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Mice Model
    • 5.4.6.4 Services
    • 5.4.6.5 Application
    • 5.4.6.6 End User
    • 5.4.6.7 Technology
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Mice Model
    • 5.4.7.4 Services
    • 5.4.7.5 Application
    • 5.4.7.6 End User
    • 5.4.7.7 Technology
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Mice Model
    • 5.5.1.4 Services
    • 5.5.1.5 Application
    • 5.5.1.6 End User
    • 5.5.1.7 Technology
  • 5.5.2 United Kingdom
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Mice Model
    • 5.5.2.4 Services
    • 5.5.2.5 Application
    • 5.5.2.6 End User
    • 5.5.2.7 Technology
  • 5.5.3 France
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Mice Model
    • 5.5.3.4 Services
    • 5.5.3.5 Application
    • 5.5.3.6 End User
    • 5.5.3.7 Technology
  • 5.5.4 Italy
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Mice Model
    • 5.5.4.4 Services
    • 5.5.4.5 Application
    • 5.5.4.6 End User
    • 5.5.4.7 Technology
  • 5.5.5 Spain
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Mice Model
    • 5.5.5.4 Services
    • 5.5.5.5 Application
    • 5.5.5.6 End User
    • 5.5.5.7 Technology
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Mice Model
    • 5.5.6.4 Services
    • 5.5.6.5 Application
    • 5.5.6.6 End User
    • 5.5.6.7 Technology
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Mice Model
    • 5.6.1.4 Services
    • 5.6.1.5 Application
    • 5.6.1.6 End User
    • 5.6.1.7 Technology
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Mice Model
    • 5.6.2.4 Services
    • 5.6.2.5 Application
    • 5.6.2.6 End User
    • 5.6.2.7 Technology
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Mice Model
    • 5.6.3.4 Services
    • 5.6.3.5 Application
    • 5.6.3.6 End User
    • 5.6.3.7 Technology
  • 5.6.4 Rest of MEA
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Mice Model
    • 5.6.4.4 Services
    • 5.6.4.5 Application
    • 5.6.4.6 End User
    • 5.6.4.7 Technology

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Charles River Laboratories
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Crown Bioscience
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 The Jackson Laboratory (JAX)
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Champions Oncology
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Medicilon
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 TheraIndx Lifesciences Pvt. Ltd
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Noble Life Sciences Inc
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Creative Biolabs Inc
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 BioDuro
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 EPO Berlin-Buch GmbH
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 WuXi AppTec
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 XenTech
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Urosphere
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Oncodesign Services
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Pharmatest Services
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Inotiv
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 GemPharmatech
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Altogen Biosystems
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Abnova Corporation
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Taconic Biosciences
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us